Results 111 to 120 of about 161,729 (326)

First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its ...
Nassr Nassr   +12 more
wiley   +1 more source

Notes from the field: The Inflation Reduction Act and Enbrel

open access: yes
Arthritis &Rheumatology, Accepted Article.
Charles L Bennett   +6 more
wiley   +1 more source

Expanding the Horizons of Phototherapy: A Review on the Superior Performance of Chalcogen‐Based Photosensitizers and Photothermal Agents for Cancer Therapy

open access: yesChemPhotoChem, EarlyView.
This review summarizes recent progress in chalcogen (S, Se, Te)‐incorporated photosensitizers and photothermal agent design. It explores synthetic strategies, spectroscopic and computational characterization, and in vitro/in vivo evaluations, showcasing the potential of these compounds for photodynamic and photothermal therapies.
Subhrakant Jena   +3 more
wiley   +1 more source

Model of pathogenesis of psoriasis. Part 2. Local processes [PDF]

open access: yesarXiv, 2012
Analytical research of results of experimental and theoretical studies on pathogenesis of psoriatic disease is carried out. The new model of pathogenesis - skin reaction to systemic psoriatic process SPP is formulated. ... Psoriatic inflammation is regarded as a reaction of the skin immune system to activity of Mo-R and DC-R involved in derma from ...
arxiv  

New Glycoconjugates Containing Selenium and Polyphenols. Stereoselective Synthesis by Pummerer‐like Rearrangement

open access: yesEuropean Journal of Organic Chemistry, Accepted Article.
In the last 20 years the exploitation of antioxidant activity of selenobased compounds has improved, just due to the use of Ebselen, a selenocompound, as a Glutathione peroxidase (GPx) mimic. However, their clinical use seems to be compromised by the low solubility in water.
Claudia González   +6 more
wiley   +1 more source

Synthetic Biology‐Based Engineering Living Therapeutics for Antimicrobial Application

open access: yesExploration, EarlyView.
This perspective highlights synthetic biology‐driven antibacterial strategies, focusing on three innovative approaches: engineered bacteriophages for precision bacterial targeting, reprogrammed microbes that detect quorum‐sensing signals or metabolites to release antimicrobials, and engineering mammalian cells that recognize pathogen‐associated ...
Shun Huang   +4 more
wiley   +1 more source

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

open access: yesExploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu   +5 more
wiley   +1 more source

Long‐term improvement in the appearance of hypertrophic scars following a single treatment with acoustic subcision—A single center proof‐of‐concept study

open access: yesLasers in Surgery and Medicine, Volume 54, Issue 10, Page 1251-1260, December 2022., 2022
Abstract Introduction and Objectives Fibrosis, including hypertrophic scar formation, is a pathological condition characterized by excessive production and accumulation of collagen, and loss of tissue architecture, in response to wound healing. Alterations in the extracellular matrix (ECM) biomechanical properties may be important in modulating ...
Brenda LaTowsky   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy